Jerzy Supronik

955 total citations
11 papers, 707 citations indexed

About

Jerzy Supronik is a scholar working on Rheumatology, Orthopedics and Sports Medicine and Hematology. According to data from OpenAlex, Jerzy Supronik has authored 11 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Rheumatology, 5 papers in Orthopedics and Sports Medicine and 4 papers in Hematology. Recurrent topics in Jerzy Supronik's work include Bone health and osteoporosis research (5 papers), Rheumatoid Arthritis Research and Therapies (4 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Jerzy Supronik is often cited by papers focused on Bone health and osteoporosis research (5 papers), Rheumatoid Arthritis Research and Therapies (4 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Jerzy Supronik collaborates with scholars based in United States, Poland and Switzerland. Jerzy Supronik's co-authors include Eva Dokoupilová, Hanno B. Richards, Patrick Durez, Sophie Hugot, Shephard Mpofu, Mark C. Genovese, Sang‐Heon Lee, Takashi Ikawa, Herbert Kellner and Jacob Aelion and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Journal of Bone and Mineral Research and Annals of the Rheumatic Diseases.

In The Last Decade

Jerzy Supronik

10 papers receiving 685 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jerzy Supronik United States	6	360	281	196	165	162	11	707
Melek Güler-Yüksel Netherlands	14	847 2.4×	136 0.5×	96 0.5×	197 1.2×	218 1.3×	19	992
Gisela Ruiz Heiland Germany	7	308 0.9×	154 0.5×	88 0.4×	85 0.5×	101 0.6×	9	586
Carmen Castro Spain	15	461 1.3×	307 1.1×	28 0.1×	159 1.0×	40 0.2×	41	767
R. J. Reece United Kingdom	6	412 1.1×	133 0.5×	35 0.2×	136 0.8×	31 0.2×	8	499
Yoshie Sanayama Japan	10	332 0.9×	171 0.6×	62 0.3×	95 0.6×	10 0.1×	17	582
Saida Boudaoud France	12	174 0.5×	220 0.8×	108 0.6×	29 0.2×	20 0.1×	16	714
Eva Tomero Spain	12	304 0.8×	153 0.5×	36 0.2×	78 0.5×	12 0.1×	31	470
Kenneth J. Scalapino United States	10	176 0.5×	379 1.3×	162 0.8×	32 0.2×	13 0.1×	12	706
D. P. C. de Rooy Netherlands	12	441 1.2×	77 0.3×	64 0.3×	80 0.5×	28 0.2×	14	551
Birgit Görtz Austria	10	272 0.8×	67 0.2×	354 1.8×	46 0.3×	146 0.9×	17	743

Countries citing papers authored by Jerzy Supronik

Since Specialization

Citations

This map shows the geographic impact of Jerzy Supronik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerzy Supronik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerzy Supronik more than expected).

Fields of papers citing papers by Jerzy Supronik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerzy Supronik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerzy Supronik. The network helps show where Jerzy Supronik may publish in the future.

Co-authorship network of co-authors of Jerzy Supronik

This figure shows the co-authorship network connecting the top 25 collaborators of Jerzy Supronik. A scholar is included among the top collaborators of Jerzy Supronik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerzy Supronik. Jerzy Supronik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Pluskiewicz, Wojciech, Jerzy Supronik, Corinne Petit-Frère, et al.. (2025). LUMIADE 3: Therapeutic Equivalence of Denosumab Biosimilar FKS518 to Reference Product in Postmenopausal Osteoporosis. Journal of the Endocrine Society. 9(12). bvaf164–bvaf164.

Seefried, Lothar, Serge Ferrari, Ombretta Viapiana, et al.. (2025). A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis. Osteoporosis International. 36(12). 2497–2507. 1 indexed citations

Reginster, Jean‐Yves, E. J. Czerwiński, Krzysztof Wilk, et al.. (2024). Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis. Osteoporosis International. 35(11). 1919–1930. 6 indexed citations

Chung, Yoon‐Sok, Bente Langdahl, E. J. Czerwiński, et al.. (2024). SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial. Bone. 192. 117371–117371. 1 indexed citations

Langdahl, Bente, Yoon‐Sok Chung, E. J. Czerwiński, et al.. (2024). Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12. The Journal of Clinical Endocrinology & Metabolism. 110(6). e1951–e1958. 4 indexed citations

Deodhar, Atul, Jerzy Supronik, Alan Kivitz, et al.. (2024). Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo‐Controlled, Phase 3 Study. Arthritis & Rheumatology. 77(2). 163–170. 1 indexed citations

Kivitz, Alan, Ulf Wagner, Eva Dokoupilová, et al.. (2018). Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study. Rheumatology and Therapy. 5(2). 447–462. 83 indexed citations

Genovese, Mark C., Patrick Durez, Hanno B. Richards, et al.. (2014). One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. The Journal of Rheumatology. 41(3). 414–421. 83 indexed citations

Buttgereit, Frank, John Kirwan, Jacek Szechiński, et al.. (2013). Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Annals of the Rheumatic Diseases. 72(2). 204–210. 131 indexed citations

10.

Genovese, Mark C., Patrick Durez, Hanno B. Richards, et al.. (2012). Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Annals of the Rheumatic Diseases. 72(6). 863–869. 227 indexed citations

11.

Recker, Robert R., Pierre D. Delmas, Johan Halse, et al.. (2007). Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure. Journal of Bone and Mineral Research. 23(1). 6–16. 170 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact